GlassScriptPhysician profile
Gregory Leo Salzman
NPI 1821095456
$10,967.84
in general payments reported to CMS, 2019-2025
41 companies · $2,695 in 2025
The $2,695 reported for 2025 was more than what 85% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $968 · 2020: $722 · 2021: $1,142 · 2022: $1,775 · 2023: $1,322 · 2024: $2,344 · 2025: $2,695.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,337 · Education: $24.24.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,336.63 |
| Education | $24.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,523.43 | 2019-2025 | Skyrizi, Linzess, Rinvoq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,695.42 | 2019-2025 | Xifaxan, Relistor, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $1,248.47 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Janssen Biotech, INC. | $1,090.94 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Qol Medical, LLC | $693.55 | 2019-2025 | Sucraid, Sucraid |
| Pfizer INC. | $558.28 | 2019-2025 | |
| Daiichi Sankyo INC. | $351.82 | 2019-2025 | Injectafer |
| Ironwood Pharmaceuticals, INC | $295.64 | 2019-2025 | Linzess |
| Genzyme Corporation | $174.45 | 2022-2025 | |
| Madrigal Pharmaceuticals | $172.08 | 2024-2025 | Rezdiffra, Resmetirom |
| Ipsen Biopharmaceuticals, INC | $171.34 | 2024-2025 | Iqirvo |
| Lilly USA, LLC | $165.57 | 2023-2024 | Omvoh |
| Nestle Healthcare Nutrition INC. | $152.20 | 2021-2023 | |
| Ardelyx, INC. | $133.38 | 2024-2025 | Ibsrela |
| Gilead Sciences, INC. | $126.74 | 2019-2022 |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Salzman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.